{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:12:32Z","timestamp":1788880352229,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Adolescents and young adults (AYA) with acute myeloid leukemia (AML) represent a biologically and clinically distinct population managed across pediatric and adult oncology services, with no established optimal treatment paradigm. In this single-center retrospective study, we analyzed 81 AYA patients aged 14 to 29 years with newly diagnosed AML treated at Memorial Sloan Kettering Cancer Center between 2010 and 2025. Patients were stratified by treating service, European LeukemiaNet (ELN) 2022 risk category, and induction regimen. Pediatric patients received 2 cycles of cytarabine, daunorubicin, and etoposide\u2013based induction, whereas adult patients received 1 cycle of cytarabine plus daunorubicin (7+3) induction, 3 of whom required 7+3 reinduction, followed by risk-adapted consolidation including allogeneic hematopoietic stem cell transplantation. Composite complete response rates were similar between adult and pediatric cohorts (79% vs 78%), as were rates of minimal residual disease negativity by multicolor flow cytometry among responders (63% vs 55%). Despite comparable depth of response, 5-year overall survival favored adult-service patients in both the full cohort (77.9% vs 56.7%) and the ELN 2022 intermediate\u2013adverse risk subgroup (62.7% vs 47.9%), whereas relapse-free survival was nearly identical. On multivariable analysis, ELN 2022 risk retained independent prognostic significance, whereas treatment protocol did not. These findings demonstrate that pediatric-style and adult AML regimens achieve comparable remission depth in AYA patients. The survival advantage observed with adult protocols challenges the assumption that further cytotoxic intensification improves outcomes in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020372","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:07:01Z","timestamp":1781809621000},"page":"5899-5908","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4787-7685","authenticated-orcid":false,"given":"Baher","family":"Krayem","sequence":"first","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-539X","authenticated-orcid":false,"given":"Jeetayu","family":"Biswas","sequence":"additional","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-4624","authenticated-orcid":false,"given":"Michael","family":"Rafizadeh","sequence":"additional","affiliation":[{"name":"4Department of Medicine, New York Presbyterian Weill Cornell, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Ciervo","sequence":"additional","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Famulare","sequence":"additional","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"2Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[{"name":"5Pediatric Hematologic Malignancies Service, Pediatrics Department, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Trippett","sequence":"additional","affiliation":[{"name":"5Pediatric Hematologic Malignancies Service, Pediatrics Department, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Forlenza","sequence":"additional","affiliation":[{"name":"5Pediatric Hematologic Malignancies Service, Pediatrics Department, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-1404","authenticated-orcid":false,"given":"Kavitha","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"5Pediatric Hematologic Malignancies Service, Pediatrics Department, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tallman","sequence":"additional","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-9117","authenticated-orcid":false,"given":"Mark","family":"Geyer","sequence":"additional","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"6Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Sulis","sequence":"additional","affiliation":[{"name":"5Pediatric Hematologic Malignancies Service, Pediatrics Department, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Leukemia Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"7Program in Early Drug Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"10393","key":"2026090810513266100_bib1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"2026090810513266100_bib2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.29867","article-title":"Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including \u201cnonmalignant\/noninvasive\u201d tumors","volume":"122","author":"Barr","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"2026090810513266100_bib3","first-page":"443","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2026090810513266100_bib4","unstructured":"National Cancer Institute\n          . Acute Myeloid Leukemia\u2014Cancer Stat Facts. Accessed 19 November 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"18","key":"2026090810513266100_bib5","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.3390\/cancers13184536","article-title":"Advances in the first line treatment of pediatric acute myeloid leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019","volume":"13","author":"Czoga\u0142a","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2026090810513266100_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/jcm11030504","article-title":"Pediatric acute myeloid leukemia-past, present, and future","volume":"11","author":"Reinhardt","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"2026090810513266100_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clml.2015.12.010","article-title":"Patient characteristics and outcomes in adolescents and young adults (AYA) with acute myeloid leukemia (AML)","volume":"16","author":"Pemmaraju","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2026090810513266100_bib8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026090810513266100_bib9","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1002\/cncr.28344","article-title":"Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials","volume":"119","author":"Woods","year":"2013","journal-title":"Cancer"},{"issue":"21","key":"2026090810513266100_bib10","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood.V124.21.3672.3672","article-title":"Adolescents and young adults (AYA) with acute myeloid leukemia (AML) have increased treatment-related mortality with similar outcomes \u2013 a report from the Children\u2019s Oncology Group trials AAML03P1 and AAML0531","volume":"124","author":"August","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026090810513266100_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"28","key":"2026090810513266100_bib12","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children\u2019s Oncology Group trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026090810513266100_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"19","key":"2026090810513266100_bib14","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis","volume":"7","author":"Zarnegar-Lumley","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026090810513266100_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an International Expert Panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2026090810513266100_bib16","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","article-title":"Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group","volume":"27","author":"Tsukimoto","year":"2009","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026090810513266100_bib17","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026090810513266100_bib18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.2024027904","article-title":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an International Expert Panel","volume":"147","author":"Zwaan","year":"2026","journal-title":"Blood"},{"issue":"16","key":"2026090810513266100_bib19","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"27","key":"2026090810513266100_bib20","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026090810513266100_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.2022016487","article-title":"Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report","volume":"141","author":"Turcotte","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026090810513266100_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/pbc.25713","article-title":"Acute myeloid leukemia in adolescents and young adults treated in pediatric and adult departments in the Nordic countries","volume":"63","author":"Wennstr\u00f6m","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"2026090810513266100_bib23","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1002\/cncr.27659","article-title":"Treatment outcome in older patients with childhood acute myeloid leukemia","volume":"118","author":"Rubnitz","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"2026090810513266100_bib24","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"19","key":"2026090810513266100_bib25","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Cooper","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026090810513266100_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2024-205666","article-title":"A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin (GO) to CPX-351 with GO-a report from the Children\u2019s Oncology Group","volume":"144","author":"Pollard","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026090810513266100_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2025-603","article-title":"Optimization of induction chemotherapy in pediatric patients with acute myeloid leukemia: real-world evidence to support removal of etoposide from induction 1","volume":"146","author":"Elgarten","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026090810513266100_bib28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2025-877","article-title":"Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia\u2013a report from the Children\u2019s Oncology Group study AAML1831","volume":"146","author":"Rossoff","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026090810513266100_bib29","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1182\/bloodadvances.2024014728","article-title":"Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations","volume":"9","author":"Sendker","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026090810513266100_bib30","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2022-162525","article-title":"A phase 2 randomized study comparing venetoclax and azacitidine to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"140","author":"Fathi","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5899\/2541743\/blooda_adv-2026-020372-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5899\/2541743\/blooda_adv-2026-020372-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:51:44Z","timestamp":1788879104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5899\/569209\/Outcomes-of-adolescents-and-young-adults-with-AML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020372","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}